Nathalie Moll
EFPIA represents the pharmaceutical industry operating in Europe. Together with its direct membership 40 leading pharmaceutical companies, 33 national associations representing over 1,900 companies and in collaboration with health and research players, EFPIA's mission is to create an environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
Prior to joining EFPIA, between 2010 and 2017 Nathalie was the Secretary-General of, EuropaBio ranked as the most effective European Trade Association in Brussels in 2013. She spent over 20 years working for the biotech industry at EU and national level in associations and corporate positions and held the position of Chair and Vice Chair of the International Council of Biotech Associations (ICBA).
In 2013, Nathalie won the Technovisionaries Women Innovation Award organised by Women & Technologies® while in 2009, Nathalie and the Green Biotech Team of EuropaBio were presented with the Leadership and Excellence in Advancing Ag-Biotech and Food Issues Award. Nathalie was also named one of the 15 leading women in biotech in Europe in 2017.
Nathalie holds an Honours Degree in Biochemistry and Biotechnology from St Andrews University, Scotland.
Articles: Nathalie Moll
Can Europe’s Beating Cancer Plan Make it an Innovation Leader?
Europe / The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the continent’s push to catch up with the US and China on biopharmaceutical innovation. Europe’s Beating Cancer Plan adds real momentum to the fight against cancer, promising to reduce the burden of…
Would the Last Pharmaceutical Investor in Europe Please Turn the Lights Out?
Europe / EFPIA’s Nathalie Moll highlights how Europe can reverse its decline in the global medical research standings and once again make the continent a world leader in medical innovation. If the content of the Pharmaceutical Strategy undermines the ambition of the Industrial Strategy then there is a very real, immediate and tangible risk that Europe…
A New Industrial Strategy for Europe: Win-Win for Both Economies & Health
Europe / The EFPIA’s Nathalie Moll outlines the case for a new EU-wide industrial strategy with biopharmaceuticals at its heart. The pharmaceutical industry is an area of strategic economic and social value where the EU is a global player Europe has a history as a world leader in medical innovation, and in the face of…
4 Actions to Drive Change for Women in Pharma
Opinion / On International Women’s Day 2019, EFPIA Director General Nathalie Moll outlines how far women in life sciences have come in terms of both representation and perception and highlights four actions that industry professionals can take today to drive further change. Equality is giving everyone the same thing, equity is giving people different things to ensure…
EFPIA, Nathalie Moll : “Patients at Front and Centre”
Patients / The Director General of EFPIA (European Federation of Pharmaceutical Industries and Associations) discusses what they are doing to put patients at the forefront of their business. Actively listening to patient experiences, patient challenges and exchanging insights must shape how EFPIA develops its thinking, its dialogue with others, its policy and the positions we advocate.…
